Moving from transplant as a treatment to transplant as a cure
Sam Kant, Daniel C. Brennan
Sam Kant, Daniel C. Brennan
Published April 6, 2020
Citation Information: J Clin Invest. 2020;130(5):2189-2191. https://doi.org/10.1172/JCI136475.
View: Text | PDF
Commentary

Moving from transplant as a treatment to transplant as a cure

Abstract

Immunosuppression continues to be a necessary component of transplantation, despite its association with a multitude of adverse effects. Numerous efforts have been made to circumvent the need for immunosuppression by using various techniques to achieve donor hyporesponsiveness. In this issue of the JCI, Morath et al. take this endeavor forward. Prior to transplantation, the researchers infused recipients with donor-modified immune cells and achieved immunologic hyporesponsiveness. This successful phase I trial also provides a possible avenue for achieving transplantation without the requisite immunosuppression.

Authors

Sam Kant, Daniel C. Brennan

×

Figure 1

A brief history of time: tolerance from discovery to application.

Options: View larger image (or click on image) Download as PowerPoint
A brief history of time: tolerance from discovery to application. Timeli...
Timeline detailing the evolution of understanding immunologic tolerance and subsequent efforts to achieve it. RAR, renal allograft recipient; SAR, skin allograft recipient.